French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular ...

DelveInsight's 'NK Cell Therapy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline NK cell ...

With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy ...

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...

Conventional natural killer (cNK) cells, known for their crucial role in tumor immunity, face hurdles in penetrating tumor tissues and maintaining their function within the tumor microenvironment.

The hair follicle is a dynamic miniature organ. Its permanent portion opens to the skin surface, communicates with sebaceous ...